Mutation in PBRM1 plays a suppressing role in ccRCC [26] and occurs at a lower frequency in the C2 subtype (37%) than in the C1 subtype (44%), indicating that C2 may be more sensitive to immunotherapy (Supplementary Figure 3H, 3I). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.